Larimar Therapeutics Inc

Larimar Therapeutics Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.34
  • Today's Change-0.41 / -8.63%
  • Shares traded170.98k
  • 1 Year change+4.08%
  • Beta0.5265
Data delayed at least 15 minutes, as of Mar 22 2023 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that are ineffective or have no treatments available. Its cell penetrating peptide (CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in a Phase I clinical program.

  • Revenue in USD (TTM)0.00
  • Net income in USD-35.36m
  • Incorporated2005
  • Employees26.00
  • Location
    Larimar Therapeutics IncTHREE BALA PLAZA EAST. SUITE 506BALA CYNWYD 19004United StatesUSA
  • Phone+1 (617) 622-4003
  • Fax+1 (302) 655-5049
  • Websitehttps://larimartx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
ALX Oncology Holdings Inc0.00-123.48m196.03m58.00--0.746-----3.03-
Adaptimmune Therapeutics PLC - ADR27.15m-165.46m196.71m534.00--2.39--7.25-1.03-1.030.16840.49770.068--6.6350,838.95-41.44-40.76-49.29-47.20-----609.46-701.17----0.00--341.50-6.42-4.66--3.52--
Foghorn Therapeutics Inc.19.23m-108.88m197.31m161.00--1,761.72--10.26-2.62-2.620.46230.00270.0416--0.1282119,428.60-23.55---26.53-------566.27------0.00--1,357.77---7.46------
Annexon Inc0.00-141.95m201.47m80.00--0.8236-----2.86-2.860.004.840.00----0.00-49.62-44.08-53.76-46.89------------0.00-------8.92--63.01--
ACRO Biomedical Co Ltd896.50k-15.79m204.14m----414.79--227.71-0.2629-0.26290.01490.00821.411.80-----2,479.75---2,959.87--25.26---1,761.25--2.15-14,096.830.1377--74.07---6,454.13------
Larimar Therapeutics Inc0.00-35.36m205.53m26.00--1.85-----1.55-1.550.002.560.00----0.00-34.48-46.88-38.11-52.34------------0.00------30.18--12.70--
Alpha Tau Medical Ltd0.00-33.76m206.02m94.00--1.95-----0.5007-0.50070.001.530.00----0.00-41.59---43.95-------------20.010.00-------23.80------
Zomedica Corp18.93m-17.01m208.44m85.00--0.7795--11.01-0.0174-0.01740.01930.27290.06761.8914.40222,705.90-6.08-17.78-6.21-18.3372.12---89.88-384.7815.46--0.0065--358.01--7.44--74.64--
Fennec Pharmaceuticals Inc0.00-21.28m209.95m10.00--74.82-----0.8168-0.81680.000.10680.00----0.00-75.43-59.18-82.67-64.40-------38,331.77---32.690.8992---100.00--4.21------
Natures Sunshine Products Inc421.91m-390.00k210.76m800.00--1.4818.210.4995-0.0177-0.017721.697.481.731.9836.72527,387.500.22515.270.32447.5469.7973.010.13043.001.24--0.007935.64-4.994.29-101.35--6.76--
Ocugen Inc0.00-81.35m215.75m84.00--2.51-----0.3787-0.37870.000.37930.00----0.00-75.89-83.81-86.12-96.15-------446,793.90----0.0265-------39.38--74.43--
Data as of Mar 22 2023. Currency figures normalised to Larimar Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

75.85%Per cent of shares held by top holders
HolderShares% Held
Deerfield Management Co. LPas of 31 Dec 202216.94m39.15%
CHI Advisors LLCas of 31 Dec 20223.47m8.03%
Perceptive Advisors LLCas of 31 Dec 20222.86m6.61%
Woodline Partners LPas of 31 Dec 20221.94m4.49%
Opaleye Management, Inc.as of 31 Dec 20221.56m3.61%
Verition Fund Management LLCas of 31 Dec 20221.48m3.41%
Mangrove Partnersas of 31 Dec 20221.29m2.99%
Great Point Partners LLCas of 31 Dec 20221.27m2.94%
The Vanguard Group, Inc.as of 31 Dec 20221.07m2.48%
Janus Henderson Investors US LLCas of 31 Dec 2022927.27k2.14%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.